



Research Article

Copy Right@ Maedeh Kojouri

Performance of Commercially Antibody-based assays for Covid-19 Detection

Maedeh Kojouri*

Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy

Department of Infectious Diseases, National Institute of Health, Italy

*Corresponding author: Maedeh Kojouri, Department of Public Health and Infectious Diseases, Sapienza University of Rome. Virology Laboratory, Department of Infectious Diseases, National Institute of Health, Rome, Italy Viale Regina Elena 299, 00161 Rome, Italy.

To Cite This Article: Maedeh Kojouri, Performance of Commercially Antibody-based assays for Covid-19 Detection. 2020 - 9(6). AJBSR.MS.ID.001453. DOI: 10.34297/AJBSR.2020.09.001453.

Received: 📅 July 13, 2020; Published: 📅 August 12, 2020

Abstract

The ongoing SARS-CoV-2 pandemic caused by novel coronavirus has become a threat to international public health. To tackle this pandemic reliable and rapid immunodiagnostic strategies are required. This study will briefly review the antibody diagnosis methods and recent clinical studies in this regard. The sensitivity and specificity after two weeks are considered to examine the late stages response of the disease. Among current studies on serology testing, 27 recent publications used commercial assays to diagnose IgM and IgG against SARS-CoV2 are discussed in this paper. A total of 54 kit-testing for antibodies, 20 are based on ELISA principles using serum or plasma samples with a sensitivity range of 55.6 % and 100% for IgG and between 77.3 % and 82.7 % for IgM. The specificity for both IgG and IgM ranges between 87.5 % to 100%. Twenty-seven kits are using lateral flow platforms and thirteen kits using luminescent immunoassays, including ten chemiluminescence immunoassay (CLIA) with sensitivity between 64 % and 97% for both IgM and IgG and 75.6% to 100% for IgG. The specificity is reported between 85% to 100% and 90.9 to 100%, respectively. Two Electrochemiluminescence Immunoassay (ECLIA) also showed high sensitivity and specificity for both antibodies. Antibody-based serology testing for SARS CoV-2 would be clinically important as a determination to return to work in society. Currently focusing on healthcare workers would be critical; however, there will be a significant need for serology-based testing to enable individuals to return to work or school safely in the overcoming months.

Key words: COVID-19; SARS-CoV-2; Antibody testing; Serological test

Introduction

The diagnosis of COVID-19 is mainly based on the polymerase-chain-reaction (PCR) assay. Although PCR is high in sensitivity, there is a possibility of false-negative results. Numerous diagnosis immunoassays are developed to test COVID-19, including fluorescence assays, chemiluminescence immunoassays (CLIAs), enzyme-linked immunosorbent assays (ELISA), rapid antibody immunochromatographic test, and point-of-care test (POCT). Although there is a variation among test methods, they are mainly testing for the presence of two types of blood antibody, IgM and IgG or both. However, the timeline varies, and people respond

differently to infection; these tests might detect antibodies by two or three weeks after symptom onset. These tests are not meant generally to active diagnosis infection but are able to identify prior infection. Many of these testing assays have not been validated yet, and their actual sensitivity and specificity are not fully understood.

Materials and Methods

Search strategy

PubMed, Embase, Medline, CAB Abstracts, ISI Web of Science, BIOSIS, LILACS, Cochrane library, CINAHL, AMED, National



Research Register and In Process were searched applying the search terms "COVID-19", "SARS-CoV-2", "antibody testing", and "serological test", from December 2019 to June 2020. The studies using non-commercial kits and the ones which performed serology tests for less than two weeks have been excluded from this review.

Data extraction

From each publication, the following data were extracted: first author's last name, year of publication, the study name, follow up time, number of positive cases, number of control case, sensitivity and specificity of the kit for each Ig protein, method of testing and the kits manufacture company, country where the study was conducted.

Diagnosis of COVID-19

Immunological and serological assays

Analytical methods that use antibodies for detection are referred to as immunoassays. The reasonably specific binding of an antibody to their target makes immunoassays an effective method

for the detection of analyzing complex biological matrices. Several types of immunoassays are used clinically in different designs, detection mechanisms, and how the assay reagents are combined with the sample.

ELISA

To perform the ELISA test, the wells of the plate are coated with the antigen of interest. By filling wells with the dilution of patient serum, the antibodies against the antigen will bind to the antigen fixed to the bottom of the walls in positive cases. Later the wells are washed out to remove unbound antibodies. Further, a solution of an animal antibody against human antibodies is added. The second antibody is covalently conjugated to an enzyme. The wells are washed out again this time to remove any unbound enzyme-conjugated antibody. Finally, a colorogenic enzyme substrate solution is added. The interaction of the substrate with the enzyme on the second antibody generates visible color. The development of the color in the wells with a specific antibody can be seen with a naked eye or quantified with an electronic plate reader (Figure 1) [1].




Figure 1: Different type of ELISA test,

Direct ELISA: wells are coated by antigen; the substrate binds to the primary antibody.

Indirect ELISA: A secondary antibody binds to the primary antibody to interact with the substrate. Sandwich ELISA: wells are coated with the capture antibody, the antigen will be incubated between capture antibody and primary antibody, an enzyme-conjugated secondary antibody binds to this complex.

Lateral flow assay

In a lateral flow assay, the sample is added to the sample application pad at one end of the strip. The sample then migrates to the conjugate release pad, where a detection particle that has been conjugated to a biological component of the assay is held. The sample and the detection reagent migrate to the reaction membrane, where a second biological component of the assay has been immobilized in a test line. The detection reagent binds of the control further along the membrane to indicate that the assay has

run successfully. The analysis is either captured at the test line or continues to migrate until it reaches the absorbent wicking pad at the end of the strip (Figure 2) [1].

Luminescent analytical system

The luminescent immunoassay is a technique capable of identifying specific antigenic molecules in the sample fluid, using the antibody and antigen labeled by an enzyme. There are several types of luminescent immunoassay, including chemiluminescent

analytical system (CLIA) and electrochemiluminescence Immunoassay (ECLIA). In ECLIA, the species emit light as a result of electron transfer reaction generated by electrodes, while in CLIA, the light is the product of the chemical reaction.

Plaque-reduction neutralization assay

The presence of infection can also be detected using the plaque assay. Indicator cells that are permissive to infection are needed to perform the test. Sample contain viruses are added to previously cultured cells in tenfold serial dilution. The indicator cells are then washed and infected with diffract dilution of the virus. The

overlayer suspension viscosity increases by using some agarose mix with a phosphate buffer saline, to ensure that each infected cell only infects its immediate neighbors. To make infection result more visible, the overlayer is peeled off, and the cells are fixed and stained using Coomassie brilliant blue dissolved in ethanol and acetic acid. After washing off all infected cells stained strongly blue in a compliant layer, however, any initial site of infection left a visible plaque, an area with no cells on the dish which appears white against the blue background. A range of different density plaques found in each plate is used to calculate platform unite (PFU) and expressed as a concentration pfu per milliliter (Figure 3) [3].




Figure 2: Latera Flow Assay
Patients sample including blood, serum, or plasma is added to the sample application pad, then the sample will migrate along the membrane for detection.




Figure 3: Neutralization Plaque Assay
Use to quantify the titer of neutralizing antibodies for a virus.

Result and Discussion

In total, 27 studies including 2183 previously confirmed patient for COVID 19 were included in this review. Serological assays with the goal of finding IgM and IgG proteins are most effective within the few days after the onset of initial symptoms, and they are not advised as an acute phase diagnostic method. Several medical provisioner companies, scientific and research centers, have made great effort to develop the best diagnosis assays. A summary of recent studies using several commercial assays is presented in Table 1. Twenty ELISA kits are tested using a serum or plasma sample. Montesinos et al. investigated that Maglumi™ IgG/IgM tests show less sensitivity than the Euroimmun IgG/IgA test (84.4 % versus 64.3 %). They also test three different lateral flow assays with sensitivity around (91 %–94 %) after 14 days of symptom onset [4].

Another clinical study by Xiang et al. reported that there is no significant difference between the sensitivity of ELISA and colloidal gold-immunochromatographic assay for both IgM and IgG testing [5]. Jan van et al. have tested seven rapid IgG/IgM tests and the Euroimmun IgA/IgG ELISA for antibodies against SARS-CoV-2. They found higher sensitivity for IgG in lateral flow assays compared to ELISA (92% versus 89.5%) after 14 days of symptoms onset [6]. Of the 20 ELISA based kits reported, the overall sensitivity range between 55.6 % and 100% for IgG and between 77.3 % and 82.7 % for IgM. The specificity for both IgG and IgM ranges between 87.5 % to 100%. Plebani et al. have tested Maglumi (Snibe), Liaison (Diasorin), iFlash (Yhlo), Euroimmun (Medizinische Labordiagnostika AG) and Wantai (Wantai Biological Pharmacy) assays and they reported diagnostic sensitivities and specificities above 93.8% and 85.9%, respectively for all CLIA assays [7]. Thirteen luminescent immunoassays are tested, including ten chemiluminescence immunoassay (CLIA) with sensitivity between 64 % and 97% for both IgM and IgG and 75.6% to 100% for IgG. The specificity is reported between 85% to 100% and 90.9 to 100%, respectively [4, 7-11].

The colloidal gold-labeled immunochromatography assays have also been tested in three studies for both IgG and IgM. Presenting the sensitivity between 68.6% and 82.4% and the specificity between 96.2% and 100% [5,12,13]. Two Electrochemiluminescence Immunoassay (ECLIA) antibody also showed high sensitivity and specificity for both IgG and IgM antibodies [10,14-30].

Conclusion

As SARS-CoV-2 progresses over time, and the virus will be cleared from the immune system, it becomes more difficult to detect the viral RNA and viral protein using RT-PCR. However, the specific antibody produced against SARS-CoV-2 by the immune system can be detected using immunoassays. Reliable immunoassays tests can identify individuals who have already been infected and may not

have been diagnosed at the time. The positive antibody test suggests that individuals may have gained immunity, or reinfection may not be as severe as the primary one. Identifying individuals who have already had infection is more important from a population health perspective than an individual's health prepositive. These individuals may help to identify the priority for vaccination or may be able to donate blood to critically sick patients who are fighting infection. During the pandemic COVID-19 reliable diagnostic test that targets both infected and recovered patients are needed to help combat the virus.

Acknowledgment

Maedeh Kojouri is funded by Virology Department at The Italian National Institute of Health (Istituto Superiore di Sanità, ISS).

References

1. K Shah, P Maghsoudlou (2016) Enzyme-linked immunosorbent assay (ELISA): The basics. *Br J Hosp Med* 77(7): C98-C101.
2. EB Bahadır, MK Sezgintürk (2016) Lateral flow assays: Principles, designs, and labels. *TrAC - Trends Anal Chem* 82: 286-306.
3. NMA Okba, MA Müller, W Li, C Wang, H Corine, et al. (2020) SARS-CoV-2 specific antibody responses in COVID-19 patients. 1-18.
4. I Montesinos, D Gruson, B Kabamba, H Dahma, S Van den, et al. (2020) Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. *J Clin Virol* 128: 104413.
5. J Xiang, M Yan, H Li, T Liu, C Lin, et al. (2020) Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19). *MedRxiv*.
6. J Van Elslande, E Houben, M Depypere, A Brackener, S Desmet, et al. (2020) Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin Microbiol Infect* 26(8): 1082-1087.
7. M Plebani, A Padoan, D Negrini, B Carpinteri, L Sciacovelli, et al. (2020) Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? *Clin Chim Acta* 509: 1-7.
8. A Padoan, C Cosma, L Sciacovelli, D Faggian, M Plebani, et al. (2020) Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. *ClinChem Lab Med* 58(7): 1081-1088.
9. M Infantino, V Grossi, B Lari, R Bambi, A Perri, et al. (2020) Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience. *JMed Virol* 1-5.
10. N Kohmer, S Westhaus, C Rühl, S Ciesek, HF Rabenau, et al. (2020) Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin Virol* 129: 104480.
11. Y Jin, M Wang, Z Zuo, C Fan, F Ye, et al. (2020) Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. *Int J Infect Dis* 94: 49-52.
12. B Shen, Y Zheng, X Zhang, W Zhang, D Wang, et al. (2020) Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. *Am J Transl Res* 12 (14): 1348-1354.
13. Y Pan, X Li, G Yang, J Fan, Y Tang, et al. (2020) Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. *JInfect*.

14. M Egger, C Bundschuh, K Wiesinger, C Gabriel, M Clodi, et al. (2020) Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDITM enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. *Clin Chim Acta* 18-21.
15. M Döhla, C Boesecke, B Schulte, CDiegmann, E Sib, et al. (2020) Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity, *Public Health*. 182: 170-172.
16. Y L Lee, CH Liao, P Y Liu, C YCheng, MY Chung, et al. (2020) Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. *JInfect* 81(2): e55-e58.
17. L Spicuzza, A Montineri, R Manuele, C Crimi, M P Pistorio, et al. (2020) Reliability and usefulness of a rapid IgM-IgG antibody test for the diagnosis of SARS-CoV-2 infection: A preliminary report. *J Infect* 81(2): e53-e54.
18. WLi, LLiu, GKou, YZheng, YDing, et al. (2020) Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. *JClin Microbiol* 58(6): e00461-20.
19. FPérez García, R Pérez Tanoira, J Romanyk, T Arroyo, P Gómez Herruz, et al. (2020) Alltest rapid lateral flow immunoassays is reliable in diagnosing SARS-CoV-2 infection from 14 days after symptom onset: A prospective single-center study. *JClin Virol* 129: 104473.
20. I Cassaniti, F Novazzi, F Giardina, F Salinaro, M Sachs, et al. (2020) Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. *J Med Virol* 1-4.
21. L Liu, W Liu, Y Zheng, X Jiang, G Kou, et al. (2020) A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. *Microbes Infect* 2: 1-6.
22. R Lassaunière, AFrische, ZBHarboe, AC Nielsen, A Fomsgaard, et al. (2020) Evaluation of nine commercial SARS-CoV-2 immunoassays. *MedRxiv*.
23. T Hoffman, K Nissen, J Krambrich, B Rönnerberg, D Akaberi, et al. (2020) Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2. *Infect EcolEpidemiol*10(1): 1754538.
24. A Jääskeläinen, E Kekäläinen, H Kallio Kokko, L Mannonen, EKortela, et al. (2020) Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples, *Euro Surveill*. 25(18): 1-8.
25. K Imai, S Tabata, M Ikeda, S Noguchi, Y Kitagawa, et al. (2020) Clinical evaluation of an immunochromatographic IgM/IgG antibody assay and chest computed tomography for the diagnosis of COVID-19. *JClinVirol*128: 104393.
26. B Lou, T D Li, S F Zheng, Y Y Su, Z Y Li, et al. (2020) Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset. *Eur Respir J* 19: 2000763.
27. B Demey, N Daher, C François, J P Lanoix, G Duverlie, et al. (2020) Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. *J Infect* 81(2): e6-e10.
28. J Zhao, Q Yuan, H Wang, W Liu, X Liao, et al. (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. *Clin Infect Dis* 1-22.
29. F Xiang, X Wang, X He, Z Peng, B Yang, et al. (2020) Ma, Antibody Detection and Dynamic Characteristics in Patients with COVID-19. *Clin Infect Dis* 1-23.
30. A Krüttgen, CG Cornelissen, M Dreher, M Hornef, M Imöhl, et al. (2020) Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. *JClin Virol* 128-104394.